Ahmed AH, et al. - The bifold aim of this trial was to gauge the clinical features and to investigate the factors related to overall survival in primary vitreoretinal lymphoma (PVRL) and ocular adnexal (OA)–uveal diffuse large B-cell lymphoma (DLBCL). A variation of 17.7% was noted in the 5-year survival in PVRL vs OA-uveal DLBCL. Additionally, greater overall survival was reported in ophthalmic DLBCL than in DLBCL located outside the central nervous system and ophthalmic regions. Younger age (≤60 years) and gross total resection illustrated a link with increased survival.

Methods

• The enrollment of this retrospective analysis constituted 396 patients with ophthalmic DLBCL from January 1, 1973, through December 31, 2014.
• It utilized the Surveillance, Epidemiology, and End Results database.
• The median follow-up was 39.0 months (interquartile range, 5.1-72.9 months).
• It recruited all patients diagnosed with primary DLBCL of the eye or retina (PVRL) or the eyelid, conjunctiva, choroid, ciliary body, lacrimal gland, or orbit (OA-uveal lymphoma).
• The exclusion criteria were patients diagnosed at autopsy or with additional neoplastic disease.
• Patient demographic characteristics, disease location, treatment modalities, and overall survival served as the primary outcome measure.

Results

• Herein, forty-seven patients with PVRL (24 women [51.1%] and 23 men [48.9%]) and 349 with OA-uveal DLBCL (192 women [55.0%] and 157 men [45.0%]) presented with a similar mean (SD) age at diagnosis (69.6 [12.3] vs 66.1 [17.7] years).
• There was no variation in the use of surgery or radiation therapy by location.
• A Cox proportional hazards regression model ascertained that age older than 60 years correlated with increased risk for death (hazard ratio [HR], 2.7; 95% CI, 1.9-4.0; P < .001), for all PVRL and OA-uveal DLBCL.
• A connection was discovered between the gross total resection with a decreased risk for death (HR, 0.5; 95% CI, 0.3-0.9; P = .04).
• In contrast, the radiation therapy was not.
• The 5-year overall survival among patients with PVRL was 41.4% (SE, 8.6%); among those with OA-uveal DLBCL, 59.1% (SE, 2.8%; Mantel-Cox test, P = .007).
• Lower median overall survival was noted in PVRL (38.0 months; 95% CI, 14.2-61.8 months) than in OA-uveal DLBCL (96.0 months; 95% CI, 67.3-124.7 months; Mantel-Cox test, P = .007).
• Furthermore, higher median overall survival in ophthalmic-only disease was found (84.0 months; 95% CI, 63.2-104.8 months) than that in primary DLBCL that occurred outside the central nervous system and ophthalmic regions (46.0 months; 95% CI, 44.4-47.6 months; Mantel-Cox test, P < .001).